temozolomide has been researched along with Necrosis in 28 studies
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed." | 7.80 | Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014) |
| "The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line." | 7.77 | Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 7.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 7.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| " Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 7.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| "Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 6.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
| "Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy." | 5.62 | Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021) |
| "Osthole was the most effective." | 5.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
| "Malignant melanomas are highly resistant to chemotherapy." | 5.35 | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009) |
| "Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease." | 5.32 | In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004) |
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma." | 5.12 | Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. ( Chalmers, L; Chamberlain, MC; Glantz, MJ; Sloan, AE; Van Horn, A, 2007) |
| "The aim of the study was to investigate the anticancer potential of LY294002 (PI3K inhibitor) and temozolomide using glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells." | 4.02 | Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment. ( Bądziul, D; Hułas-Stasiak, M; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Pawelec, J; Pawlikowska-Pawlęga, B; Reichert, M; Rzeski, W; Sumorek-Wiadro, J; Wasiak, M; Wertel, I; Zając, A, 2021) |
| "As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed." | 3.80 | Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014) |
| "The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line." | 3.77 | Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 3.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 3.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy." | 3.74 | MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008) |
| " Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 3.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| "Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 2.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
| "Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity." | 2.61 | Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019) |
| "Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
| "Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy." | 1.62 | Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021) |
| "Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology." | 1.62 | Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021) |
| "Osthole was the most effective." | 1.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
| "Glioblastoma is the most common and aggressive glioma, characterized by brain invasion capability." | 1.48 | Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets. ( Bonacorso, HG; Costa Nunes, F; Creczynski-Pasa, TB; de Melo, LJ; Feitosa, SC; Martins, MAP; Rode, M; Silva, AH; Silva, LB; Winter, E; Zanatta, N, 2018) |
| "Lycopene is a fat soluble red-orange carotenoid pigment present in tomato that reduces the risk for prostate cancer, a common malignancy among men." | 1.39 | Lycopene modulates growth and survival associated genes in prostate cancer. ( Bright, JJ; Kanakasabai, S; Rafi, MM; Reyes, MD, 2013) |
| "Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis." | 1.39 | Malignant glioma with angiocentric features. ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013) |
| "Malignant melanomas are highly resistant to chemotherapy." | 1.35 | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009) |
| "Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease." | 1.32 | In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 6 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Marinho, MAG | 1 |
| da Silva Marques, M | 1 |
| Lettnin, AP | 1 |
| de Souza Votto, AP | 1 |
| de Moraes Vaz Batista Filgueira, D | 1 |
| Horn, AP | 1 |
| Sumorek-Wiadro, J | 2 |
| Zając, A | 2 |
| Bądziul, D | 2 |
| Langner, E | 3 |
| Skalicka-Woźniak, K | 1 |
| Maciejczyk, A | 2 |
| Wertel, I | 2 |
| Rzeski, W | 3 |
| Jakubowicz-Gil, J | 3 |
| Guo, L | 1 |
| Li, X | 1 |
| Chen, Y | 1 |
| Liu, R | 1 |
| Ren, C | 1 |
| Du, S | 1 |
| Park, YW | 1 |
| Choi, D | 1 |
| Park, JE | 1 |
| Ahn, SS | 1 |
| Kim, H | 1 |
| Chang, JH | 1 |
| Kim, SH | 1 |
| Kim, HS | 1 |
| Lee, SK | 1 |
| Gao, F | 1 |
| Zhao, W | 1 |
| Li, M | 1 |
| Ren, X | 1 |
| Jiang, H | 1 |
| Cui, Y | 1 |
| Lin, S | 1 |
| Pawlikowska-Pawlęga, B | 1 |
| Pawelec, J | 1 |
| Wasiak, M | 1 |
| Hułas-Stasiak, M | 1 |
| Reichert, M | 1 |
| Yu, A | 1 |
| Faiq, N | 1 |
| Green, S | 1 |
| Lai, A | 1 |
| Green, R | 1 |
| Hu, J | 1 |
| Cloughesy, TF | 1 |
| Mellinghoff, I | 1 |
| Nghiemphu, PL | 1 |
| Costa Nunes, F | 1 |
| Silva, LB | 1 |
| Winter, E | 1 |
| Silva, AH | 1 |
| de Melo, LJ | 1 |
| Rode, M | 1 |
| Martins, MAP | 1 |
| Zanatta, N | 1 |
| Feitosa, SC | 1 |
| Bonacorso, HG | 1 |
| Creczynski-Pasa, TB | 1 |
| Winter, SF | 1 |
| Loebel, F | 1 |
| Loeffler, J | 1 |
| Batchelor, TT | 1 |
| Martinez-Lage, M | 1 |
| Vajkoczy, P | 1 |
| Dietrich, J | 1 |
| Jablonska, PA | 1 |
| Diez-Valle, R | 1 |
| Pérez-Larraya, JG | 1 |
| Moreno-Jiménez, M | 1 |
| Idoate, MÁ | 1 |
| Arbea, L | 1 |
| Tejada, S | 1 |
| Garcia de Eulate, MR | 1 |
| Ramos, L | 1 |
| Arbizu, J | 1 |
| Domínguez, P | 1 |
| Aristu, JJ | 1 |
| Rafi, MM | 1 |
| Kanakasabai, S | 1 |
| Reyes, MD | 1 |
| Bright, JJ | 1 |
| Iuchi, T | 1 |
| Hatano, K | 1 |
| Kodama, T | 1 |
| Sakaida, T | 1 |
| Yokoi, S | 1 |
| Kawasaki, K | 1 |
| Hasegawa, Y | 1 |
| Hara, R | 1 |
| Karpel-Massler, G | 1 |
| Westhoff, MA | 1 |
| Kast, RE | 1 |
| Dwucet, A | 1 |
| Nonnenmacher, L | 1 |
| Wirtz, CR | 1 |
| Debatin, KM | 1 |
| Halatsch, ME | 1 |
| Rubner, Y | 1 |
| Muth, C | 1 |
| Strnad, A | 1 |
| Derer, A | 1 |
| Sieber, R | 1 |
| Buslei, R | 1 |
| Frey, B | 1 |
| Fietkau, R | 1 |
| Gaipl, US | 1 |
| Peca, C | 1 |
| Pacelli, R | 1 |
| Elefante, A | 1 |
| Del Basso De Caro, ML | 1 |
| Vergara, P | 1 |
| Mariniello, G | 1 |
| Giamundo, A | 1 |
| Maiuri, F | 1 |
| Naumann, SC | 1 |
| Roos, WP | 2 |
| Jöst, E | 1 |
| Belohlavek, C | 1 |
| Lennerz, V | 1 |
| Schmidt, CW | 1 |
| Christmann, M | 1 |
| Kaina, B | 2 |
| Yaman, E | 1 |
| Buyukberber, S | 1 |
| Benekli, M | 1 |
| Oner, Y | 1 |
| Coskun, U | 1 |
| Akmansu, M | 1 |
| Ozturk, B | 1 |
| Kaya, AO | 1 |
| Uncu, D | 1 |
| Yildiz, R | 1 |
| Eich, M | 1 |
| Dianov, GL | 1 |
| Digweed, M | 1 |
| Rusthoven, KE | 1 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Kleinschmidt-DeMasters, BK | 1 |
| Kavanagh, BD | 1 |
| Gaspar, LE | 1 |
| Lillehei, K | 1 |
| Waziri, A | 1 |
| Damek, DM | 1 |
| Chen, C | 1 |
| Matuschek, C | 1 |
| Bölke, E | 1 |
| Nawatny, J | 1 |
| Hoffmann, TK | 1 |
| Peiper, M | 1 |
| Orth, K | 1 |
| Gerber, PA | 1 |
| Rusnak, E | 1 |
| Lammering, G | 1 |
| Budach, W | 1 |
| Raghavan, D | 1 |
| Boxerman, J | 1 |
| Jeyapalan, S | 1 |
| Rogg, J | 1 |
| Lu, JQ | 1 |
| Patel, S | 1 |
| Wilson, BA | 1 |
| Pugh, J | 1 |
| Mehta, V | 1 |
| Fuggetta, MP | 1 |
| D'Atri, S | 1 |
| Lanzilli, G | 1 |
| Tricarico, M | 1 |
| Cannavò, E | 1 |
| Zambruno, G | 1 |
| Falchetti, R | 1 |
| Ravagnan, G | 1 |
| Stamatakos, GS | 1 |
| Antipas, VP | 1 |
| Uzunoglu, NK | 1 |
| Chamberlain, MC | 1 |
| Glantz, MJ | 1 |
| Chalmers, L | 1 |
| Van Horn, A | 1 |
| Sloan, AE | 1 |
| Brandes, AA | 1 |
| Franceschi, E | 1 |
| Tosoni, A | 1 |
| Blatt, V | 1 |
| Pession, A | 1 |
| Tallini, G | 1 |
| Bertorelle, R | 1 |
| Bartolini, S | 1 |
| Calbucci, F | 1 |
| Andreoli, A | 1 |
| Frezza, G | 1 |
| Leonardi, M | 1 |
| Spagnolli, F | 1 |
| Ermani, M | 1 |
| Brandsma, D | 1 |
| Stalpers, L | 1 |
| Taal, W | 1 |
| Sminia, P | 1 |
| van den Bent, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT01591577] | Phase 2 | 50 participants (Actual) | Interventional | 2012-12-07 | Active, not recruiting | ||
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for temozolomide and Necrosis
| Article | Year |
|---|---|
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob | 2021 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
4 trials available for temozolomide and Necrosis
| Article | Year |
|---|---|
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administra | 2017 |
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc | 2019 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
20 other studies available for temozolomide and Necrosis
| Article | Year |
|---|---|
Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy?
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell | 2021 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation.
Topics: Adult; Aged; Brain; Chemoradiotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Female; Gliob | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromones; Drug | 2021 |
Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.
Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Ge | 2018 |
Lycopene modulates growth and survival associated genes in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carotenoids; Cell Cycle; Cell Line, Tumor; Cell | 2013 |
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Typ | 2009 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor | 2011 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dru | 2004 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer G | 2006 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |